Search
margetuximab
Indications:
- ERBB2(HER2)-positive advanced breast cancer in conjunction with chemotherapy
Mechanism of action:
- chimeric, Fc-engineered, immune-activating anti-ERBB2 IgG1 monoclonal antibody that shares epitope specificity & Fc-independent antiproliferative effects with trastuzumab
- Fc engineering of margetuximab alters 5 amino acids from wild-type IgG1 to increase affinity for activating Fc-gamma receptor CD16A & to decrease affininty for inhibitory Fc-gamma receptor CD32B
- effects proposed to increase activation of innate & adaptive anti-ERBB2 immune responses, relative to trastuzumab [1]
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
antineoplastic monoclonal antibody
References
- Rugo HS, Im SA, Cardoso F et al
Efficacy of Margetuximab vs Trastuzumab in Patients With
Pretreated ERBB2-Positive Advanced Breast Cancer. A Phase 3
Randomized Clinical Trial.
JAMA Oncol. Published online January 22, 2021
PMID: 33480963
https://jamanetwork.com/journals/jamaoncology/fullarticle/2775599